Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAIME LANDMAN

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1346204690
CMS profile
105508
Location
AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$161.81

7 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $161.81 7

By paying entity

PY2022 · entire year · sorted by reported total

Paying entityAmountRecords
GlaxoSmithKline, LLC. $63.18 3
ABBVIE INC. $28.56 1
Genentech USA, Inc. $24.49 1
OptiNose US, Inc. $24.31 1
GENZYME CORPORATION $21.27 1

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAIME LANDMAN

NPI 1346204690 · CMS profile ID 105508

Allopathic & Osteopathic Physicians / Allergy & Immunology

AVENTURA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346204690?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346204690?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346204690?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JAIME LANDMAN, NPI 1346204690, CMS profile ID 105508, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–7 of 7 matching records. This page contains 7 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1346204690?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

7 matching records · $161.81 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 7 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–7 of 7.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $21.4308/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944809855 CMS
GENZYME CORPORATION $21.2706/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938838233 CMS
GlaxoSmithKline, LLC. $20.5005/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944809857 CMS
Genentech USA, Inc. $24.4903/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 950787555 CMS
OptiNose US, Inc. $24.3103/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928088493 CMS
ABBVIE INC. $28.5603/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 893138099 CMS
GlaxoSmithKline, LLC. $21.2502/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944809859 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $290.90 12
PY2020 $140.24 7
PY2021 $151.53 7
PY2022 $161.81 7
PY2023 $108.04 5
PY2025 $185.24 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $751,515.35 131
PY2024 Principal investigator $525,143.48 126
PY2023 Principal investigator $497,961.58 102
PY2022 Principal investigator $447,451.34 86
PY2021 Principal investigator $586,667.15 102
PY2020 Recipient $11,702.26 1
PY2020 Principal investigator $473,131.41 28
PY2019 Recipient $1,525.00 1
PY2019 Principal investigator $615,806.88 59

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

29 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,800.50 12/31/2020 Non-covered Recipient Entity
Florida Ctr For Allergy And Asthma
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 736743755
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,952.32 12/31/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106447
Principal investigator 1 GlaxoSmithKline, LLC. $4,611.44 12/21/2020 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA CARE
A RANDOMISED, DOUBLE-BLIND, PARALLEL GROUP, MULTICENTRE, STRATIFIED, S No dispute reported 06/30/2026 965525753
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $440.01 12/11/2020 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 740106391
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $880.02 12/08/2020 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 740106389
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $880.02 11/25/2020 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 740106387
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,000.00 11/24/2020 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 740106377
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $3,000.00 11/24/2020 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 740106379
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $880.02 11/17/2020 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 740106385
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $880.02 11/11/2020 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 740106383
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,760.04 10/22/2020 Non-covered Recipient Entity
Florida Center For Allergy & Asthma Research
CONNected Electronic Inhalers Asthma Control Trial 1 ("CONNECT 1"), a 12-Week Treatment, Multicenter, Open-Label, Randomized, Parallel Group Comparison, Feasibility Study to Evaluate the Effectiveness of the Albuterol eMDPI Digital System, to Optimize Outcomes in Patients at Least 13 Years of Age or Older With Asthma No dispute reported 06/30/2026 740106381
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $1,350.00 10/15/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106433
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,985.00 08/14/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106427
Principal investigator 1 Novartis Pharmaceuticals Corporation $11,605.23 08/11/2020 Non-covered Recipient Entity
FLORIDA CENTER ALLERGY ASTHMA RESEARCH
A 12-WEEK, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF CSJ117, WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS ? 18 YEARS OF AGE WITH SEVERE UNCONTROLLED ASTHMA. No dispute reported 06/30/2026 721491321
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $35,550.00 07/23/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106423
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $22,050.00 06/22/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106419
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $10,800.00 05/21/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106415
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $20,250.00 04/27/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106405
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $5,000.00 04/27/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106407
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,650.00 04/22/2020 Non-covered Recipient Entity
Florida Ctr For Allergy And Asthma
A Phase 2 Randomized, Double-blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI3506 in Adult Subjects with Moderate-to-severe Atopic Dermatitis No dispute reported 06/30/2026 736747879
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,450.00 03/18/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106401
Principal investigator 1 Eli Lilly and Company $281,132.00 03/17/2020 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES No dispute reported 06/30/2026 728742319
Principal investigator 1 Eli Lilly and Company $55.89 03/06/2020 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES No dispute reported 06/30/2026 728736279
Recipient Eli Lilly and Company $11,702.26 02/25/2020 Covered Recipient Physician A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 CROSSOVER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF LY3454738 IN ADULTS WITH CHRONIC SPONTANEOUS URTICARIA INADEQUATELY CONTROLLED WITH H1-ANTIHISTAMINES No dispute reported 06/30/2026 728720489
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,000.00 02/24/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106397
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,447.50 02/18/2020 Non-covered Recipient Entity
Florida Ctr For Allergy And Asthma
A Randomized Double-Blind Parallel Group Multi-Center 24-Week Study Comparing the Efficacy and Safety of Three Doses of PT001 to Placebo and Open-label Spiriva Respimat in Subjects With Persistent Asthma No dispute reported 06/30/2026 736749697
Principal investigator 1 Novartis Pharmaceuticals Corporation $4,515.00 01/29/2020 Non-covered Recipient Entity
FLORIDA CENTER FOR ALLERGY AND ASTHMA RESEARCH
A TWO TREATMENT EPOCH RANDOMIZED PLACEBO CONTROLLED MULTI CENTERED PARALLEL GROUP STUDY TO ASSESS THE SAFETY OF QAW039 WHEN ADDED TO EXISTING ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED SEVERE ASTHMA No dispute reported 06/30/2026 721491327
Principal investigator 1 Teva Pharmaceuticals USA, Inc. $9,900.00 01/28/2020 Non-covered Recipient Entity
Florida Center for Allergy and Asthma Research
A Randomized, Blinded, Parallel Group, Placebo-Controlled, Multiple Dose, Multicenter Study to Compare the Therapeutic Equivalence of Fluticasone Propionate Pressurized Metered Dose Inhaler, 110 mcg, to Flovent HFA 110 mcg, in Adult Subjects With Asthma No dispute reported 06/30/2026 740106393
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,306.40 01/01/2020 Non-covered Recipient Entity
FLORIDA CENTER ALLERGY ASTHMA RESEARCH
A 12 WEEK MULTICENTER RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY TO ASSESS THE EFFICACY AND SAFETY OF QAW039 WHEN ADDED TO STANDARD OF CARE ASTHMA THERAPY IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 721491325